Hansen Medical to Present at the UBS Global Life Sciences Conference
14 9월 2011 - 5:01AM
Marketwired
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible
catheter robotics and the developer of robotic technology for
accurate 3D control of catheter movement, announced today that
President and CEO Bruce Barclay is scheduled to present at the UBS
Global Life Sciences Conference. The conference is being held
September 19-21, 2011 at the Grand Hyatt New York in New York City.
Hansen Medical is scheduled to present on Wednesday, September 21,
2011 at 9:00 a.m. Eastern Time.
Hansen Medical will provide a live webcast of the audio
presentation. Interested parties may access the live webcast by
visiting the investor relations section of Hansen Medical's web
site at www.hansenmedical.com. A replay of the webcast will be
available at the site after the presentation.
About Hansen Medical, Inc. Hansen Medical,
Inc., based in Mountain View, California, develops products and
technology using robotics for the accurate positioning,
manipulation and control of catheters and catheter-based
technologies. The company's Sensei® X Robotic Catheter System and
Artisan Control Catheter were cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in electrophysiology (EP) procedures. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the United
States, the Sensei System is not approved for use in guiding
ablation procedures; this use remains experimental. The U.S.
product labeling therefore provides that the safety and
effectiveness of the Sensei X System and Artisan catheter for use
with cardiac ablation catheters in the treatment of cardiac
arrhythmias, including atrial fibrillation (AF), have not been
established. In the European Union, the Sensei X System and Artisan
catheter are cleared for use during EP procedures, such as guiding
catheters in the treatment of AF, and the Lynx® Robotic Ablation
Catheter is cleared for the treatment of AF. The company's
Magellan™ Robotic System, which is intended to facilitate
navigation to anatomical targets in the peripheral vasculature and
subsequently provide a conduit for manual placement of therapeutic
devices, has undergone conformity assessment and CE marking and is
commercially available in the European Union. The NorthStar™
Robotic Catheter and related accessories designed for use with the
Magellan Robotic System are not yet CE marked. In the U.S., the
Magellan™ Robotic System, the NorthStar™ Robotic Catheter and
accessories are the subject of a current filing with the FDA and
are not commercially available. Additional information can be found
at www.hansenmedical.com.
Hansen Medical, Heart Design, Hansen Medical & Heart Design,
Sensei, Artisan and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical 650.404.5800 Matt Clawson Allen & Caron
Inc 949.474.4300 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024
Hansen Medical, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Hansen Medical, Inc. News Articles